Axovant Gene Therapies Stock Price

0.00 (0.0%)
Upgrade to Real-Time
Regular Market
Volume 0
Bid Price 2.09
Ask Price 2.11
News -
Company Name Stock Ticker Symbol Market Type
Axovant Gene Therapies Ltd AXGT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 2.10 20:00:00
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume
0 0 -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 2.10 USD


Draw Mode:

Axovant Gene Therapies Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 99.22M 47.25M 28.55M $ - $ - -2.93 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - -

more financials information »

Axovant Gene Therapies News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AXGT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months0.
6 Months0.
1 Year0.
3 Years6.426.931.413.69555,816-4.32-67.29%
5 Years9.8419.841.417.15766,638-7.74-78.66%

Axovant Gene Therapies Description

Axovant Gene Therapies Ltd is a clinical-stage company that is focused on gene therapy for neurodegenerative diseases. The company is developing its pipeline for the treatment of debilitating diseases, including Parkinson's disease, GM1 gangliosidosis, and GM2 gangliosidosis. It currently has three clinical-stage programs which include AXO-Lenti-PD program for Parkinson's disease, AXO-AAV-GM1 program for GM1 gangliosidosis, and AXO-AAV-GM1 program for GM2 gangliosidosis (including Tay-Sachs and Sandhoff diseases).

Your Recent History
Axovant Ge..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now